Reuters logo
BRIEF-Stemline Therapeutics presents SL-401 updated stage 1 and 2 data from ongoing pivotal trial in BPDCN
2017年6月23日 / 下午2点05分 / 3 个月前

BRIEF-Stemline Therapeutics presents SL-401 updated stage 1 and 2 data from ongoing pivotal trial in BPDCN

June 23 (Reuters) - Stemline Therapeutics Inc

* Stemline Therapeutics presents SL-401 updated stage 1 and 2 data from ongoing pivotal trial in BPDCN and safety experience across multiple indications, today at EHA

* Stage 3 is fully enrolled and data will be reported, along with further updated stage 1 and 2 data, in 2H17

* Depending on results of this ongoing phase 2 trial, co intend to file a BLA for SL-401 in BPDCN in 4Q17/1Q18

* In first-line BPDCN patients treated at 12 ug/kg/day (n=16), median overall survival (os) has not been reached

* Stages 1 and 2 enrolled 32 bpdcn patients, of which 19 were first-line and 13 patients were relapsed/refractory Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below